Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesContext Therapeutics Inc

Context Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.2003 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
765516
Market Cap
33.48M

Momentum Score

…

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.19
Low
0.21
High
52 Week Price Range
0.34
Low
3.62
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Context Therapeutics Inc is a clinical-stage biotechnology company developing targeted therapies for cancer. Its long-term growth may be driven by successful clinical trial readouts, regulatory approvals, and partnerships that could support development and commercialization, which may appeal to investors seeking exposure to high-upside oncology programs.
Investors should monitor material risks from clinical and regulatory failure, high cash burn and dilution from future financings, intense competition in oncology, and uncertain commercialization prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.20
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-76.14%
Net Debt
-65.88M
ROCE
-65.65%
Diluted EPS TTM
-0.49

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -36.12M -26.73M -23.96M -14.84M -10.46M
Net income -36.12M -26.73M -23.96M -14.29M -7.43M
Selling general administrative 7.85M 7.22M 7.29M 7.79M 3.63M
Selling and marketing expenses - - 0.01M - -
Gross profit -0.12M -0.05M -0.01M - -
Reconciled depreciation 0.02M 0.01M 0.01M 0.01M -
Ebit - -29.92M -25.07M -15.38M -10.53M
Ebitda -39.70M -29.91M -25.06M -14.37M -7.31M
Depreciation and amortization - 0.01M 0.01M 1.01M 3.21M
Operating income -39.70M -29.92M -25.07M -15.38M -10.53M
Other operating expenses 39.70M 29.92M 25.07M 14.88M 7.44M
Interest expense - - - 0.55M 0.06M
Interest income 3.38M 3.20M 1.27M 0.55M -
Net interest income 3.38M 3.20M 1.27M 0.55M -0.06M
Income tax expense - - -0.00M -0.55M -3.02M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 39.70M 29.92M 25.07M 14.88M 7.44M
Cost of revenue 0.12M 0.05M 0.01M - -
Total other income expense net 3.58M 3.20M 1.11M 0.55M 0.07M
Net income from continuing ops -36.12M -26.73M -20.75M -14.84M -10.46M
Net income applicable to common shares - - - - -10.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 68.49M 98.13M 16.06M 37.97M 51.31M
Other current assets 2.36M 3.47M 1.60M 2.36M 1.62M
Total liab 8.02M 2.86M 4.19M 3.21M 3.03M
Total stockholder equity 60.47M 95.27M 11.87M 34.76M 48.27M
Other current liab 5.38M 1.19M 1.81M 2.22M 1.21M
Common stock 0.09M 0.09M 0.02M 0.02M 0.02M
Capital stock 0.09M 0.09M 0.02M 0.02M 0.02M
Retained earnings -130.90M -94.78M -68.05M -44.09M -29.25M
Other assets - - 0.00M 0.00M 0.05M
Cash 66.00M 94.43M 14.45M 35.50M 49.64M
Total current liabilities 8.02M 2.75M 4.19M 3.21M 3.03M
Net debt -65.88M -94.21M -14.45M -35.44M -49.64M
Short term debt 0.11M 0.11M - 0.06M -
Short long term debt total 0.11M 0.22M - 0.06M -
Other stockholder equity 191.29M 189.96M 79.91M 78.83M 77.51M
Total current assets 68.35M 97.90M 16.05M 37.85M 51.26M
Net tangible assets - - - - 48.27M
Accounts payable 2.53M 1.45M 2.38M 0.94M 1.83M
Accumulated other comprehensive income - - - - -51.31M
Non currrent assets other - - -0.00M 0.03M 0.05M
Non current assets total 0.14M 0.23M 0.02M 0.11M 0.05M
Capital lease obligations 0.11M 0.22M 0.00M 0.06M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -14.76M 0.00M -0.54M -0.25M
Change to liabilities - - - - -0.87M
Total cashflows from investing activities -2.03M -14.76M - - -0.25M
Total cash from financing activities -0.02M 109.29M 0.00M -0.10M 58.39M
Change to operating activities - - - - -1.36M
Net income -36.12M -26.73M -23.96M -14.84M -10.46M
Change in cash -28.43M 79.98M -21.05M -14.19M 49.34M
Begin period cash flow 94.43M 14.45M 35.50M 49.69M 0.34M
End period cash flow 66.00M 94.43M 14.45M 35.50M 49.69M
Total cash from operating activities -26.39M -14.56M -21.05M -13.55M -8.80M
Issuance of capital stock 0.00M 109.29M 0.00M 0.00M 58.39M
Depreciation 0.02M 0.01M 0.01M 0.01M -
Other cashflows from investing activities -2.00M -14.75M - - -
Other cashflows from financing activities -0.02M 109.29M - -0.41M 4.98M
Change to netincome - - - - 3.88M
Capital expenditures 0.03M 14.76M 0.00M 0.54M 0.25M
Change in working capital 6.28M -3.48M 1.78M -0.28M -2.22M
Stock based compensation 1.33M 0.84M 1.08M 0.98M 0.51M
Other non cash items 2.11M 14.79M 0.05M 0.58M 3.37M
Free cash flow -26.42M -29.31M -21.05M -14.09M -9.05M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CNTX
Context Therapeutics Inc		 -
-%		 0.20 - - - 0.86 1.60
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Context Therapeutics Inc

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

2001 Market Street, Philadelphia, PA, United States, 19103

267 225 7416

https://www.contexttherapeutics.com

15

Name Title Year Born
Mr. Martin A. Lehr Co-Founder, Pres, CEO & Director 1984
Ms. Jennifer Minai-Azary CFO & Treasurer 1978
Mr. Alex C. Levit Esq. Chief Legal Officer & Corp. Sec. 1979
Dr. Felix Kim Ph.D. Co-founder & Chair of Scientific Advisory Board NA
Mr. Christopher Beck M.B.A. Sr. VP of Operations NA
Dr. Tarek Sahmoud M.D., Ph.D. Chief Medical Officer 1961
Dr. Evan G. Dick Sr. VP of R&D 1952
Ms. Elizabeth Nemchik CPA Controller NA
Mr. Martin A. Lehr Co-Founder, President, CEO & Director 1984
Mr. Alex C. Levit Esq. Chief Legal Officer & Corporate Secretary 1979

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…